The variety of US employers who cowl weight problems drugs, together with Wegovy from Novo Nordisk that belongs to a category of GLP-1 medicine, may almost double subsequent yr, in response to a survey.The survey of 502 employers by Accolade, an organization that gives healthcare applications for employers, and analysis agency Savanta stated 43 per cent of the employers it polled may cowl GLP-1 medicine in 2024 in comparison with 25 per cent that cowl them now.
GLP-1s, brief for glucagon-like peptide 1 agonists, are used to deal with sort 2 diabetes and weight reduction.
“For the 43 per cent planning to supply protection subsequent yr, we advocate a physician-led strategy that guides who needs to be prescribed GLP-1 drugs and tips on how to make them a part of a holistic well being administration plan,” Accolade Affiliate Chief Medical Officer James Wantuck stated.
Practically all the businesses which are protecting GLP-1 medicine plan to maintain protecting them subsequent yr, in response to the survey.
Employers that cowl weight-loss medicine are dealing with a spike of their healthcare prices due to the rising reputation of Wegovy.
Gross sales of Novo Nordisk’s Wegovy and its diabetes drug Ozempic, each of which include the energetic ingredient semaglutide, have surged within the final yr. Ozempic is getting used “off label” for weight reduction as properly.
Prescriptions of Eli Lilly’s Mounjaro, one other GLP-1 diabetes drug that’s anticipated to be authorized for weight reduction in america this yr, have soared too.
Advantages advisor Aon stated 1 per centage level of the 8.5 per cent improve in employer healthcare prices it predicted for subsequent yr could be pushed by worker take-up of weight-loss medicine.